DANAHER CORP /DE/ (DHR)

Danaher is a global science and technology innovator focused on improving human health. It consists of more than 15 operating companies with leadership positions in biotechnology, life sciences and diagnostics. The businesses are united by the Danaher Business System (DBS), a set of continuous-improvement tools and a culture built on five Core Values. Danaher pursues three strategic priorities: strengthening its competitive advantage through DBS, enhancing its portfolio through strategic capital allocation, and attracting and retaining talent. It grows partly through acquisitions, investments and alliances, and it may divest businesses based on strategic fit. The company traces its origins to the early 1980s and its founders, Steven M. and Mitchell P. Rales.

The company reports three segments. Biotechnology offers equipment, consumables, software and services for developing and manufacturing biological medicines, including antibodies, recombinant proteins, vaccines and cell, gene and mRNA therapies. It includes a bioprocessing business and a discovery and medical business, and its key brands are CYTIVA and PALL. Life Sciences offers instruments, consumables, services and software for studying DNA, RNA, proteins, metabolites and cells. It covers flow cytometry and lab automation, mass spectrometry and microscopy instruments. It also covers consumables such as custom oligonucleotides, antibodies and reagents, plus filtration, separation and purification products for applications such as microelectronics, aircraft, refineries, power generation and food and beverage. Its brands include ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX. Diagnostics offers clinical instruments, consumables, software and services for diagnosing disease. It includes molecular diagnostics and clinical diagnostics (clinical lab, acute care and pathology), under brands such as BECKMAN COULTER, CEPHEID, HEMOCUE, LEICA BIOSYSTEMS, MAMMOTOME and RADIOMETER.

Customers include pharmaceutical and biopharmaceutical companies, biotechnology companies, contract manufacturers and development organizations, academic and research institutions, hospitals, physicians' offices, reference laboratories, pathologists and blood banks. Industrial users of filtration products are also served. The customer base is geographically diverse. In 2025, 41% of total sales were in the United States, and the company distinguishes developed markets from high-growth markets such as Eastern Europe, the Middle East, Africa, Latin America and most of Asia. Many products and services are sold on a recurring basis, mainly through a direct sales model, supplemented by independent distributors.

Research, manufacturing, sales, distribution, service and administrative facilities are located in about 50 countries, with manufacturing in North America, Europe and Asia, and in Australia for Diagnostics. Raw materials include metal and electronic components, chemistries, OEM products and plastics, bought from many sources worldwide. No single supplier is material, though some components come from a single or limited number of qualified suppliers. Danaher owns numerous patents, trademarks and other intellectual property, but none is considered material to any segment or to the whole business. It faces a wide variety of competitors, from regional and specialized firms to large companies, and none competes across all of its product lines or markets. Competition is increasing from well-resourced entrants, low-cost manufacturers, emerging technology companies and market consolidation. As of December 31, 2025, Danaher had approximately 60,000 employees.